Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

ABSTRACT:

Introduction

IgA nephropathy is the most common primary glomerulonephritis and a leading cause of kidney failure worldwide. Treatments that target the underlying immune drivers of the disease to improve long-term patient outcomes are needed. Sibeprenlimab, a selective A Proliferation-Inducing Ligand (APRIL) inhibitor that significantly decreases pathogenic galactose-deficient IgA1 (Gd-IgA1) production and immune complex formation, is being investigated in the ongoing phase 3 VISIONARY trial. Here, we summarize the overall study design and report on the baseline characteristics of patients enrolled in the trial.

Methods

VISIONARY is a multicenter, double-blind, placebo-controlled trial (ClinicalTrials.gov identifier, NCT05248646; study date of registration: 2022-02-18). Adult

SUBMITTER: Perkovic V 

PROVIDER: S-EPMC12712463 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature